Research
Hormonal
Central obesity, measured by waist circumference (WC) or waist-to-hip ratio (WHR), is independently associated with an increased risk of nonalcoholic fatty liver disease (NAFLD), even after adjusting for general obesity (BMI).
Monitor your waist circumference, not just your weight. If your waist is large, your risk for fatty liver disease is elevated, even if your BMI is normal. Prioritize reducing abdominal fat through diet and physical activity to mitigate this risk.
GoodSupportsHIGH confidence
Central obesity may pose a greater threat to national health than general obesity, although both are independently associated with increased risk of NAFLD.
Why this rating
Based on a meta-analysis of 20 studies with moderate to high quality scores, though heterogeneity was high.
Source
Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index
Qing Pang · World Journal of Gastroenterology · 2015
DOI 10.3748/wjg.v21.i5.1650
Meta-analysis · 20 studiesCited 211×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →